Mirdametinib
- Generic Name
- Mirdametinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3IN2O4
- CAS Number
- 391210-10-9
- Unique Ingredient Identifier
- 86K0J5AK6M
- Background
PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- C17 Council
- Target Recruit Count
- 50
- Registration Number
- NCT06666348
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 24
- Registration Number
- NCT06159166
- Locations
- πΊπΈ
Johns Hopkins Hospital, Baltimore, Maryland, United States
Mirdametinib in Histiocytic Disorders
- Conditions
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 40
- Registration Number
- NCT06153173
- Locations
- πΊπΈ
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Murdoch Childrens Research Institute
- Target Recruit Count
- 50
- Registration Number
- NCT05983159
- Locations
- π¦πΊ
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
π¦πΊThe Royal Children's Hospital, Parkville, Victoria, Australia
Mirdametinib + BGB-3245 in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- SpringWorks Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05580770
- Locations
- πΊπΈ
UC San Diego Moores Cancer Center, La Jolla, California, United States
πΊπΈYale-New Haven Hospital-Yale Cancer Center, New Haven, Connecticut, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT05054374
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity), Commack, New York, United States
πΊπΈMemorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT04923126
- Locations
- πΊπΈ
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 105
- Registration Number
- NCT03905148
- Locations
- π¦πΊ
The Prince of Wales Private Hospital - Specialist Medical Randwick, Randwick, New South Wales, Australia
π¦πΊBlacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
πΊπΈUniversity of California Los Angeles, Santa Monica, California, United States
MEK and MET Inhibition in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 82
- Registration Number
- NCT02510001
- Locations
- π¬π§
Oxford University Hospital NHS Trust, Oxford, United Kingdom
A Single Patient IND for PD-0325901
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Sharp HealthCare
- Registration Number
- NCT02297802
- Locations
- πΊπΈ
Sharp Healthcare, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.